Stocks · News reference
Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 10:07 AM
- Checked
- Aug 10, 2026, 10:07 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $50 to $69.
Read original at benzingaGreenwich LifeSciences shares are trading lower after the company provided clinical updates on FLAMINGO-01.
Read original at benzinga